RF Acquisition Corp II(RFAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 1158.08 | EPS (ttm) | 0.03 | Insider Own | 40.94% | Shs Outstand | 7.5M | Perf Week | -11.32% |
| Market Cap | 0.12B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.4M | Perf Month | 5.71% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | - | Inst Own | 45.8% | Short Float | 0.23% | Perf Quarter | 164.73% |
| Income | 0.00B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.07 | Perf Half Y | 208.61% |
| Sales | 0.00B | P/B | 8.28 | EPS next 5Y | - | ROA | 0.36% | Short Interest | 0.01M | Perf YTD | 213.49% |
| Book/sh | 4.07 | P/C | 5918.55 | EPS past 3/5Y | - | ROE | 0.39% | 52W High | -53.84% ($73.00) | Perf Year | 212.91% |
| Cash/sh | 0.01 | P/FCF | - | Sales past 3/5Y | - | ROIC | 0.78% | 52W Low | 276.96% ($8.94) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -86.94% | Gross Margin | - | Volatility(W/M) | 13.73% 17.67% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 5.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.04 | EPS Q/Q | -116.79% | Profit Margin | - | RSI (14) | 51.33 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.04 | Sales Q/Q | - | SMA20 | 4.88% ($32.13) | Beta | 1.65 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -1.24% ($34.12) | Rel Volume | 0.28 | Prev Close | $27.22 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 78.83% ($18.84) | Avg Volume(3M) | 0.08M | Price | $33.7 |
| IPO | 2024/7/5 | Option/Short | No/Yes | Trades | 1465 | Volume | 21,235 | Change | 23.81% |
🧬 This is a special purpose acquisition company (SPAC) pursuing a merger with Nanyang Biologics, a Singapore-based innovative AI-driven drug discovery company. The goal is to bring its unique platform technology—which leverages artificial intelligence to identify therapeutic compounds from natural products—to the public markets, driving innovation in the biotech industry.
Over the past 1 year, roughly in the middle
54% below its 1-year high.
Traded less than usual. That is 28% of its average volume.
Company yardsticks do not fit here, so profitability, valuation and earnings are left out. The other verdicts still apply.
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 45.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #1212 of 1429 in the industry
Based on market cap of $118M.
FAQ
What kind of company is RFAI?
RFAI belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of RFAI?
The market cap of RFAI is approximately $118M, ranking 4,327 within its sector.
What is the P/E ratio of RFAI?
RFAI has a P/E ratio of approximately 1158.1x, which can be used to assess its valuation relative to the Financial sector average.
What is the 52-week high and low for RFAI?
RFAI has recorded a 52-week high of $73.00 and a low of $8.94.